1. Home
  2. MYGN vs VSTS Comparison

MYGN vs VSTS Comparison

Compare MYGN & VSTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • VSTS
  • Stock Information
  • Founded
  • MYGN 1991
  • VSTS 1936
  • Country
  • MYGN United States
  • VSTS United States
  • Employees
  • MYGN N/A
  • VSTS N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • VSTS
  • Sector
  • MYGN Health Care
  • VSTS
  • Exchange
  • MYGN Nasdaq
  • VSTS Nasdaq
  • Market Cap
  • MYGN 744.7M
  • VSTS 763.0M
  • IPO Year
  • MYGN 1995
  • VSTS N/A
  • Fundamental
  • Price
  • MYGN $5.30
  • VSTS $6.13
  • Analyst Decision
  • MYGN Hold
  • VSTS Hold
  • Analyst Count
  • MYGN 15
  • VSTS 4
  • Target Price
  • MYGN $15.14
  • VSTS $11.75
  • AVG Volume (30 Days)
  • MYGN 1.9M
  • VSTS 2.8M
  • Earning Date
  • MYGN 08-05-2025
  • VSTS 08-06-2025
  • Dividend Yield
  • MYGN N/A
  • VSTS 1.82%
  • EPS Growth
  • MYGN N/A
  • VSTS N/A
  • EPS
  • MYGN N/A
  • VSTS N/A
  • Revenue
  • MYGN $831,300,000.00
  • VSTS $2,731,558,000.00
  • Revenue This Year
  • MYGN N/A
  • VSTS N/A
  • Revenue Next Year
  • MYGN $6.68
  • VSTS $0.36
  • P/E Ratio
  • MYGN N/A
  • VSTS N/A
  • Revenue Growth
  • MYGN 7.38
  • VSTS N/A
  • 52 Week Low
  • MYGN $3.81
  • VSTS $5.20
  • 52 Week High
  • MYGN $29.30
  • VSTS $17.83
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 55.01
  • VSTS 47.44
  • Support Level
  • MYGN $4.90
  • VSTS $5.62
  • Resistance Level
  • MYGN $5.29
  • VSTS $6.03
  • Average True Range (ATR)
  • MYGN 0.25
  • VSTS 0.21
  • MACD
  • MYGN 0.09
  • VSTS 0.08
  • Stochastic Oscillator
  • MYGN 93.44
  • VSTS 63.16

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

Share on Social Networks: